You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 20233640169
Dec 202397022
Jan 20246402
Feb 202454021
Mar 2024100020
Apr 2024132025
May 202488010
Jun 2024138017
Jul 2024126016
Aug 2024116019
Sep 2024110017
Oct 2024276017
Nov 2024166013
Dec 2024160020
Jan 202510009
Feb 202518019
Mar 20250014
Apr 20250022
May 20250010
Jun 20251016
Total21100478